Clinical trials: Smoldering Myeloma
Smouldering Myeloma, MGUS
Biology and Genetics of Smouldering Myeloma
Observational clinical trial recruiting Smouldering Myeloma patients (SMM) or potential SMM patients. Study involves collecting blood and bone marrow samples to determine the features of the tumour genome and BM microenvironment…
- Conditions
- Smouldering Myeloma, MGUS, Multiple Myeloma
- Trial name
- COSMOS (NCT05047107)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- University College, London
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM)
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
The study is designed to evaluate safety, immunogenicity, and preliminary anti-tumor activity of a multi-peptide immunotherapy (BB-MPI-03) at three peptide+adjuvant dose levels.
- Conditions
- Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
- Trial name
- BBMPI03 (NCT02240537)
- Testing
- Sargramostim, BB-MPI-03, Montanide
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Benovus Bio, Inc.
Myeloma
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple…
- Trial name
- NCT05055063
- Testing
- Belantamab mafodotin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.
- Trial name
- NCT02316106
- Testing
- daratumumab
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 123 people
- Sponsor
- Janssen Research & Development, LLC
Cancer, Myeloma
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
OBJECTIVES Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.
- Conditions
- Cancer, Myeloma, Multiple Myeloma
- Trial name
- NCT00983346
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Multiple Myeloma, Smoldering Multiple Myeloma
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Coronavirus
- Trial name
- NCT04727294
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- HealthTree Foundation
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
This study will test whether a plant-based diet is practical (feasible) for overweight people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM).
- Trial name
- NCT04920084
- Testing
- Plant based meals
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Smoldering Multiple Myeloma
Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
The aim of the study is to evaluate the effect of statin administration on the course of progressive Smoldering Multiple Myeloma.
- Trial name
- PSMMSS (NCT00503763)
- Testing
- Simvastatin
- Sponsor
- Meir Medical Center
Multiple Myeloma and Plasma Cell Neoplasm
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
RATIONALE: Some cancers need growth factors which are made by the body's white blood cells to keep growing.Anakinra may interfere with the growth factor and stop multiple myeloma from growing.
- Trial name
- NCT00635154
- Testing
- Anakinra (IL-1Ra), Dexamethasone acetate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Waldenstrom's Macroglobulinemia
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM), Smoldering MM, and other lymphoplasmacytic…
- Conditions
- Multiple Myeloma, Waldenstrom's Macroglobulinemia, Smoldering Multiple Myeloma, Lymphoblastic Lymphoma
- Trial name
- NCT01177527
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Dana-Farber Cancer Institute
Smoldering Multiple Myeloma
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
- Trial name
- SPOTLIGHT (NCT06212323)
- Testing
- Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Utah
Multiple Myeloma, Smoldering Multiple Myeloma
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- TRANSFORMM (NCT05361694)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Miami
Smoldering Multiple Myeloma
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma.
- Trial name
- NCT02903381
- Testing
- Nivolumab, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
This research study is evaluating the effects of a mind body medicine intervention called the Relaxation Response Resiliency Program (3RP) on stress and stress related symptoms in patients with monoclonal gammopathy of…
- Trial name
- NCT01955395
- Testing
- Relaxation Response Resiliency Program (3RP)
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
RATIONALE: Green tea extract contains ingredients that may prevent or slow the growth of monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma.
- Trial name
- NCT00942422
- Testing
- defined green tea catechin extract, gene expression analysis, protein analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Smoldering Multiple Myeloma
A Real-world Study in Participants With Smoldering Multiple Myeloma
The purpose of this study is to evaluate the real-world characteristics and outcomes of participants with smoldering multiple myeloma (SMM) overall and by high-risk and non-high-risk SMM according to (AQUILA study criteria…
- Trial name
- NCT06472778
- Where
- 29 sites in France, Germany and 3 more
- Volunteers
- 408 people
- Sponsor
- Janssen-Cilag Ltd.
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
This randomized phase III trial studies lenalidomide to see how well it works compared to a placebo in treating patients with multiple myeloma who are undergoing autologous stem cell transplant.
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT00114101
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 140 sites in United States
- Volunteers
- 460 people
- Sponsor
- National Cancer Institute (NCI)
Smoldering Multiple Myeloma
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: Lenalidomide Citarinostat (CC-96241) PVX-410
- Trial name
- NCT02886065
- Testing
- Hiltonol, Citarinostat, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00899353
- Testing
- Omega 3 Fatty Acid
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Marshall University
Smoldering Myeloma, Smoldering Multiple Myeloma
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.
- Trial name
- NCT02279394
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Dana-Farber Cancer Institute